The case for & against
Bull & Bear analysis
Bullish
McKesson Corporation (NYSE: MCK) is a leading player in the healthcare services and information technology space, specializing in pharmaceutical distribution, biopharma services, and healthcare technology solutions. With a strong emphasis on oncology and specialty medications, McKesson is positioned at a critical juncture in the evolving healthcare landscape, capitalizing on a diversified service offering to create substantial value within the healthcare supply chain. The company operates primarily in North America and focuses on improving health outcomes through community-based care.
Bull says
- ↑12% YoY revenue growth to $403B, driven by oncology and specialty.
- ↑Adjusted EPS rose 18% YoY to $39.11 in fiscal 2026.
- ↑$5.1B returned via dividends and buybacks under disciplined capital plan.
- ↑Oncology segment expansion to add ~6–7% to operating profit growth.
- ↑Ongoing tech and automation investments boost productivity and service.
- ↑High profitability and low leverage underpin stable operations and upside.
Bear says
- ↓Potential IRA impacts create reimbursement and pricing uncertainties.
- ↓Negative earnings yield and declining revisions signal waning investor confidence.
- ↓Elevated volatility risk amid price fluctuations adds uncertainty.
- ↓Integration risks from acquisitions could derail projected profit gains.
- ↓Competitive pressure may erode specialty and oncology margins over time.
- ↓Regulatory and pricing headwinds may weigh on future margin expansion.
Investment themes with MCK
Health Care Distribution↓ -0.12%
MCK · CAH · MCK
SPY↑ +0.09%
NVDA · AAPL · GOOGL
Earnings Call · Q4 2026 · Mgmt. Guidance
Updated 05-08-2026neutral
Transcript signals
Bull points
- Fiscal 2026 represents another year of exceptional financial performance. We delivered robust growth across our core strategies, while expanding operating levers through discipline execution and portfolio actions that create long-term shareholder value.
- For the full year, consolidated revenues reached $403 billion, a 12% increase. Adjusted operating profit grew 15% to $6.5 billion, and adjusted earnings for diluted share increased 18% to $39.11.
- Notably, these results exceeded the long-term growth targets that we are reaffirming today.
Bear points
- we successfully navigated the first wave of branded pharmaceutical price changes related to the Inflation Reduction Act. As expected, there was an impact to revenue growth
- Guidance does imply a bit of a step down in free cash flow, about 13% reduction year over year, despite the 10% increase in AOP.
- if he's getting reimbursed based off of ASP and the price of that drug is sort of coming down, you know, is the practice better off?
Read full transcript analysis ›